

INOVIO PHARMACEUTICALS, INC.

Form 4

April 03, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Kim Jong Joseph**

2. Issuer Name and Ticker or Trading Symbol  
**INOVIO PHARMACEUTICALS, INC. [INO]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
**660 W. GERMANTOWN PIKE  
SUITE 110**

3. Date of Earliest Transaction (Month/Day/Year)  
**03/30/2017**

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**Chief Executive Officer**

(Street)  
**PLYMOUTH MEETING, PA 19462**

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |  |
| Common Stock                    | 03/30/2017                           |  | M                              |   | 73,590 A \$ 5.08  | 2,164,887  | D  |
| Common Stock                    | 03/30/2017                           |  | S                              |   | 73,590 D \$ 6.5051  | 2,091,297  | D  |
| Common Stock                    | 03/31/2017                           |  | M                              |   | 73,590 A \$ 5.08  | 2,164,887  | D  |
| Common Stock                    | 03/31/2017                           |  | S                              |   | 73,590 D \$ 6.5739  | 2,091,297  | D  |
| Common Stock                    |                                      |  |                                |   |   | 1,750,000  | I By Family Limited                        |

| Common Stock | 33,563 | I | Partnership<br>By<br>Daughter:<br>EK |
|--------------|--------|---|--------------------------------------|
| Common Stock | 33,775 | I | By Son:<br>JK1                       |
| Common Stock | 5,975  | I | By Spouse                            |
| Common Stock | 33,533 | I | By Son:<br>JK2                       |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Common Stock Option                        | \$ 5.08  | 03/30/2017                           | 03/30/2017   | M <sup>(1)</sup>               | 73,590  | 01/18/2007 01/18/2017 <sup>(1)</sup>                     | Common Stock  | 73,590                     |
| Common Stock Option                        | \$ 5.08  | 03/31/2017                           | 03/31/2017   | M <sup>(1)</sup>               | 73,590  | 01/18/2007 01/18/2027 <sup>(1)</sup>                     | Common Stock  | 73,590                     |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                         |       |
|---|---------------|-----------|-------------------------|-------|
|   | Director      | 10% Owner | Officer                 | Other |
| Kim Jong Joseph<br>660 W. GERMANTOWN PIKE SUITE 110<br>PLYMOUTH MEETING, PA 19462 | X             |           | Chief Executive Officer |       |

## Signatures

/s/ Jong Joseph  
Kim

04/03/2017

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The term of these stock option was extended by 14 days after the expiration of the Company's blackout period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.